{"transactions":[{"id":1427804,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-20T20:27:16.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":261,"price":46,"value":12006.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 110,408 unvested RSUs."}],"balance_after":143222,"source":{"system":"sec-edgar","filing":"0000950170-24-099125","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099125/ownership.xml","form_type":"4"}},{"id":1427803,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-20T20:27:16.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":2060,"price":45.01,"value":92720.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."}],"balance_after":143483,"source":{"system":"sec-edgar","filing":"0000950170-24-099125","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099125/ownership.xml","form_type":"4"}},{"id":1483649,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-06-11T23:41:51.000Z","date":"2024-06-11","kind":"sale","planned":true,"acquired":false,"shares":1008,"price":31.27,"value":31520.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 115,565 unvested RSUs."}],"balance_after":145543,"source":{"system":"sec-edgar","filing":"0000950170-24-072168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024072168/ownership.xml","form_type":"4"}},{"id":1483648,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-06-11T23:41:51.000Z","date":"2024-06-11","kind":"sale","planned":true,"acquired":false,"shares":1628,"price":31.27,"value":50907.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":146551,"source":{"system":"sec-edgar","filing":"0000950170-24-072168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024072168/ownership.xml","form_type":"4"}},{"id":1511666,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-05-18T01:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":425,"price":28.59,"value":12150.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 119,209 unvested RSUs."}],"balance_after":148179,"source":{"system":"sec-edgar","filing":"0000950170-24-062079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024062079/ownership.xml","form_type":"4"}},{"id":1511665,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-05-18T01:06:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":1956,"price":28.2,"value":55159.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."}],"balance_after":148604,"source":{"system":"sec-edgar","filing":"0000950170-24-062079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024062079/ownership.xml","form_type":"4"}},{"id":1581409,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-03-13T01:58:16.000Z","date":"2024-03-12","kind":"sale","planned":true,"acquired":false,"shares":1030,"price":25.58,"value":26347.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.55 to $25.63, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 124,366 unvested RSUs."}],"balance_after":150560,"source":{"system":"sec-edgar","filing":"0000950170-24-030483","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030483/ownership.xml","form_type":"4"}},{"id":1581408,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-03-13T01:58:16.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":1585,"price":25.7,"value":40734.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 124,366 unvested RSUs."}],"balance_after":151590,"source":{"system":"sec-edgar","filing":"0000950170-24-030483","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030483/ownership.xml","form_type":"4"}},{"id":1584367,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-03-12T01:52:27.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":1557,"price":26.2,"value":40793.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $26.23, inclusive."}],"balance_after":153175,"source":{"system":"sec-edgar","filing":"0000950170-24-029609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024029609/ownership.xml","form_type":"4"}},{"id":1584366,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-03-12T01:52:27.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":8364,"price":25.8,"value":215791.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021 and November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.51 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Included 128,010 unvested RSUs."}],"balance_after":154732,"source":{"system":"sec-edgar","filing":"0000950170-24-029609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024029609/ownership.xml","form_type":"4"}},{"id":1612525,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-28T22:06:00.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":407,"price":25,"value":10175.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 140,510 unvested RSUs."}],"balance_after":163096,"source":{"system":"sec-edgar","filing":"0000950170-24-022242","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024022242/ownership.xml","form_type":"4"}},{"id":1643396,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-14T21:27:23.000Z","date":"2024-02-12","kind":"sale","planned":true,"acquired":false,"shares":5493,"price":25.07,"value":137709.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 145,667 unvested RSUs."}],"balance_after":163503,"source":{"system":"sec-edgar","filing":"0000950170-24-015259","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024015259/ownership.xml","form_type":"4"}},{"id":1669742,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-27T00:49:51.000Z","date":"2024-01-26","kind":"sale","planned":true,"acquired":false,"shares":100,"price":25,"value":2500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 145,667 unvested RSUs."}],"balance_after":168996,"source":{"system":"sec-edgar","filing":"0000950170-24-008063","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024008063/ownership.xml","form_type":"4"}},{"id":1714458,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-12T22:33:28.000Z","date":"2023-12-12","kind":"sale","planned":true,"acquired":false,"shares":978,"price":10.55,"value":10317.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.37 to $10.75, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 145,667 unvested RSUs."}],"balance_after":169096,"source":{"system":"sec-edgar","filing":"0001209191-23-058328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123058328/doc4.xml","form_type":"4"}},{"id":1714457,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-12T22:33:28.000Z","date":"2023-12-11","kind":"sale","planned":true,"acquired":false,"shares":1688,"price":10.72,"value":18095.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 145,667 unvested RSUs."}],"balance_after":170074,"source":{"system":"sec-edgar","filing":"0001209191-23-058328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123058328/doc4.xml","form_type":"4"}},{"id":1739237,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-16T21:29:48.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":32131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027."}],"balance_after":32131,"derivative":{"exercise_price":10.88,"expiration_date":"2033-11-14","underlying":"Common Stock","underlying_shares":32131},"source":{"system":"sec-edgar","filing":"0001209191-23-055524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123055524/doc4.xml","form_type":"4"}},{"id":1739236,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-11-16T21:29:48.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":82512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 82,512 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 149,311 unvested RSUs."}],"balance_after":171762,"source":{"system":"sec-edgar","filing":"0001209191-23-055524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123055524/doc4.xml","form_type":"4"}},{"id":1782171,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-13T23:56:07.000Z","date":"2023-09-12","kind":"sale","planned":false,"acquired":false,"shares":1707,"price":10.41,"value":17769.87,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.07 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 66,799 unvested RSUs."}],"balance_after":89250,"source":{"system":"sec-edgar","filing":"0001209191-23-049362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123049362/doc4.xml","form_type":"4"}},{"id":1856020,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-06-14T22:40:00.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":1698,"price":12.43,"value":21106.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 70,443 unvested RSUs."}],"balance_after":90957,"source":{"system":"sec-edgar","filing":"0001209191-23-037165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123037165/doc4.xml","form_type":"4"}},{"id":1952352,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-15T21:49:37.000Z","date":"2023-03-14","kind":"sale","acquired":false,"shares":7441,"price":13.33,"value":99188.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021, December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 74,087 unvested RSUs."}],"balance_after":92655,"source":{"system":"sec-edgar","filing":"0001209191-23-018979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123018979/doc4.xml","form_type":"4"}},{"id":2088157,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-12-13T22:04:51.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026."}],"balance_after":56000,"derivative":{"exercise_price":10.72,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001209191-22-060969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122060969/doc4.xml","form_type":"4"}},{"id":2088156,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-12-13T22:04:51.000Z","date":"2022-12-12","kind":"sale","acquired":false,"shares":628,"price":10.87,"value":6826.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 90,231 unvested RSUs."}],"balance_after":100096,"source":{"system":"sec-edgar","filing":"0001209191-22-060969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122060969/doc4.xml","form_type":"4"}},{"id":2088155,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-12-13T22:04:51.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 36,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 91,625 unvested RSUs."}],"balance_after":100724,"source":{"system":"sec-edgar","filing":"0001209191-22-060969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122060969/doc4.xml","form_type":"4"}},{"id":2158510,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-15T21:28:15.000Z","date":"2022-09-15","kind":"disposition_to_issuer","acquired":false,"shares":658,"price":14.05,"value":9244.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 55,625 unvested RSUs."}],"balance_after":64724,"source":{"system":"sec-edgar","filing":"0001209191-22-050123","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122050123/doc4.xml","form_type":"4"}},{"id":2231582,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-06-16T00:03:11.000Z","date":"2022-06-14","kind":"disposition_to_issuer","acquired":false,"shares":668,"price":4.95,"value":3306.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 57,019 unvested RSUs."}],"balance_after":65382,"source":{"system":"sec-edgar","filing":"0001209191-22-037145","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122037145/doc4.xml","form_type":"4"}},{"id":2335682,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-14T21:08:18.000Z","date":"2022-03-11","kind":"sale","acquired":false,"shares":640,"price":8.73,"value":5587.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,413 unvested RSUs."}],"balance_after":66050,"source":{"system":"sec-edgar","filing":"0001209191-22-018533","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122018533/doc4.xml","form_type":"4"}},{"id":2355187,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-04T00:22:39.000Z","date":"2022-03-02","kind":"sale","acquired":false,"shares":5617,"price":8.56,"value":48081.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 2, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.56 to $8.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 59,807 unvested RSUs."}],"balance_after":66690,"source":{"system":"sec-edgar","filing":"0001209191-22-015901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122015901/doc4.xml","form_type":"4"}},{"id":2473714,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-14T21:21:01.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":67935,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025."}],"balance_after":67935,"derivative":{"exercise_price":13.12,"expiration_date":"2031-12-09","underlying":"Common Stock","underlying_shares":67935},"source":{"system":"sec-edgar","filing":"0001209191-21-069422","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121069422/doc4.xml","form_type":"4"}},{"id":2473713,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-14T21:21:01.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":22307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 22,307 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 72,307 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting."}],"balance_after":72307,"source":{"system":"sec-edgar","filing":"0001209191-21-069422","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121069422/doc4.xml","form_type":"4"}},{"id":2809198,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-05T00:24:23.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 2, 2021. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 1, 2022 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":250000,"derivative":{"exercise_price":17.77,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-21-009963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924321009963/doc4.xml","form_type":"4"}},{"id":2809197,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":88191,"kind":"person","name":"Farwell Wildon","position":1,"cik":"0001847941","reported_name":"Farwell Wildon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-05T00:24:23.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 50,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on March 1, 2022."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0000899243-21-009963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924321009963/doc4.xml","form_type":"4"}}]}